NCT01226966已完成不适用
Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,152
- 试验地点
- 1
- 主要终点
- Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%
研究概览
简要总结
This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with type 2 diabetes
- •Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment
排除标准
- •Hypersensitivity (allergy) to liraglutide or to any of the excipients
- •Patient is participating in a clinical trial at the inclusion
- •Type 1 diabetes
研究组 & 干预措施
A
干预措施: liraglutide (Drug)
结局指标
主要结局
Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%
时间窗: Month 24
次要结局
- Change in HbA1c at month 6(Month 0, Month 6)
- Change in Body Weight at Month 18(Month 0, Month 18)
- Change in HbA1c at month 3(Month 0, Month 3)
- Change in HbA1c at month 12(Month 0, Month 12)
- Change in fasting plasma glucose (FPG) at month 12(Month 0, Month 12)
- Change in Body Weight at Month 3(Month 0, Month 3)
- Change in Body Weight at Month 24(Month 0, Month 24)
- Change in HbA1c at month 24(Month 0, Month 24)
- Change in fasting plasma glucose (FPG) at month 3(Month 0, Month 3)
- Change in fasting plasma glucose (FPG) at month 6(Month 0, Month 6)
- Change in fasting plasma glucose (FPG) at month 18(Month 0, Month 18)
- Change in HbA1c at month 18(Month 0, Month 18)
- Change in fasting plasma glucose (FPG) at month 24(Month 0, Month 24)
- Change in Body Weight at Month 12(Month 0, Month 12)
- Change in Body Weight at Month 6(Month 0, Month 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2DiabetesDiabetes Mellitus, Type 2NCT01484262Novo Nordisk A/S1,344
已完成
1 期
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.Metabolism and Nutrition DisorderObesityNCT02717858Novo Nordisk A/S52
已完成
1 期
A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 DiabeticsDiabetes Mellitus, Type 2DiabetesNCT00993304Novo Nordisk A/S20
已完成
4 期
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01973231Novo Nordisk A/S404
已完成
不适用
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily PracticeDiabetesDiabetes Mellitus, Type 2NCT02255266Novo Nordisk A/S1,788